Guideline-Driven Strategies in MS: De-escalating and Discontinuing Disease-Modifying Therapies

In this episode, Jeffrey Cohen, MD, Professor, Cleveland Clinic Lerner College of Medicine, and Director of the Experimental Therapeutics Program at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic, Cleveland, OH, discusses the first comprehensive recommendations for de-escalating and discontinuing disease-modifying therapies in select individuals living with multiple sclerosis developed by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).